Default company panoramic image
Logo

Euclises Pharmaceuticals, Inc.

Euclises exploits the well validated cancer target COX-2 with novel inhibitors that dramatically improve safety & anti-cancer efficacy.

  • Stage Product In Development
  • Industry Biotechnology
  • Location St. Louis, MO, USA
  • Currency USD
  • Founded October 2011
  • Employees 4

Company Summary

Euclises - founded by Celebrex inventor John Talley - is focused on novel COX-2 inhibitors with improved safety & efficacy allowing effective treatment of many cancers, such as lung, colorectal, & pancreatic. COX-2 in cancer has been appreciated, but older drugs such as Celebrex have not been effectively developed for this. Clinical studies with these, however, have validated both the impact of COX-2 in cancer & biomarkers for patient selection.

Team

  • Default avatar
    Randall Weiss
    Co-founder

  • Default avatar
    Rajesh Devraj
    President & CEO

    Over 18 years experience in drug discovery and development, business development, and strategy. Previously Sr. Vice President, Deciphera Pharmaceuticals. Prior to that served as SVP, Head of Scientific & Portfolio Strategy at Jubilant Biosys and Sr. Dir, and Res. Fellow in Med. Chem. and Discovery Res. with Pfizer R&D. Has led teams that have advanced eight candidates to clinical trials. He currently serves on SAB of Deciphera Pharmaceuticals.

  • Default avatar
    Robert Alan Beardsley
    Executive Chair

    Two decades experience leading oncology drug start-ups. Also Exec. Chair of Galera Therapeutics, a clinical-stage company backed by Novartis Ventures & NEA. Previously CEO of Galera, MSDC, Kereos & Metaphore Pharmaceuticals. Key leader in advancing seven candidates through clinical trials. Served/ serves on boards of multiple biotech/ pharmaceutical companies ranging from pre-seed to public, and has raised $100M in venture capital support.

  • Default avatar
    John Talley
    CSO

    One of the world’s most accomplished med. chemists & inventor of Celebrex®, as well as several other marketed medicines. with over 20 years of drug-making experience. He is also co-founder of SARmont, a key chemistry collaborator for the company. Previously served as SVP at Ironwood Pharmaceuticals, & in various roles at G. D. Searle. His track record in bringing drugs to market is unrivalled, with more than 200 issued U.S. patents.

  • Default avatar
    Eduardo Martinez
    VP of Drug Discovery

    Significant experience starting small chemistry-driven companies & directing drug discovery. He is also a co-founder of SARmont, a key chemistry collaborator for the company. Previously was at Medros where he led the company drug discovery operations, and at Ironwood Pharmaceuticals where he started the chemistry group and led a team of chemists to advance two candidates into the clinic.

  • Default avatar
    Robert Calcaterra
    Co-founder

  • Default avatar
    Robert Karr
    Co-founder

Advisors

  • Default avatar
    Andrew Hoyne - Polsinelli (corporate); Timothy Keane - Harness Dickey Pierce (corporate)
    Lawyer
    Unconfirmed
    Default avatar
    Judy Ballard - Right on Site (bookkeeping); Stone Carlie (tax)
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Arch Angels (Eulises Angels, LLC)
    Unconfirmed
    Default avatar
    BioGenerator
    Unconfirmed